4-Dimethoxymethyl-2-phenyl-1H-imidazole | 68283-21-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-Dimethoxymethyl-2-phenyl-1H-imidazole
• 英文别名: 5-(dimethoxymethyl)-2-phenyl-1H-imidazole
• CAS: 68283-21-6
• 化学式: C₁₂H₁₄N₂O₂
• 分子量: 218.255
• InChiKey: XVWOWPZGRZBDLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  47.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Dimethoxymethyl-2-phenyl-1H-imidazole 在 sodium hydroxide 、 碘 作用下， 以 甲醇 、 水 、 甲苯 为溶剂， 生成 3-[1(5-iodo-2-phenyl-4-imidazolyl)ethylidene]carbazic acid methyl ester
  参考文献：
  名称：

  Imidazo [1,5-d]-as-triazine-4(3H)-ones and thiones

  摘要：

  提供了替代的咪唑[1,5-d]-嘧啶-4(3H)-酮和替代的咪唑[1,5-d]-嘧啶-4(3H)-硫酮，可用作环磷酸腺苷磷酸二酯酶的抑制剂和广谱除草剂。

  公开号：

  US04107307A1
• 作为产物：
  描述：

  2-苯基-1H-咪唑-4-缩醛 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 4-Dimethoxymethyl-2-phenyl-1H-imidazole
  参考文献：
  名称：

  Imidazo [1,5-d]-as-triazine-4(3H)-ones and thiones

  摘要：

  提供了替代的咪唑[1,5-d]-嘧啶-4(3H)-酮和替代的咪唑[1,5-d]-嘧啶-4(3H)-硫酮，可用作环磷酸腺苷磷酸二酯酶的抑制剂和广谱除草剂。

  公开号：

  US04107307A1

文献信息

• Method for the control of undesired plant species using
  申请人：American Cyanamid Company

  公开号：US04168964A1

  公开（公告）日：1979-09-25

  This disclosure describes herbicidal methods for the pre- and postemergence control of undesired mono- and dicotyledonous plants using substituted imidazo[1,5-d]-as-triazin-4(3H)-ones and substituted imidazo[1,5-d]-as-triazine-4(3H)-thiones.

  本公开描述了使用取代的咪唑[1,5-d]-嘧啶-4(3H)-酮和取代的咪唑[1,5-d]-嘧啶-4(3H)-硫醚来进行对不受欢迎的单子叶和双子叶植物的前期和后期除草的除草方法。
• [EN] NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS<br/>[FR] ARYL IMIDAZOLES ET COMPOSES ASSOCIES, MODULATEURS DE RECEPTEUR C5A
  申请人：NEUROGEN CORP

  公开号：WO2003082829A1

  公开（公告）日：2003-10-09

  The invention provides Aryl substituted imidazoles, pyrazoles, pyridizines and related compounds of the Formula (I) where the ring system represented by Formula (A) is a 5 membered heteroaryl ring system, in which x is 0, A is chosen from carbon and heteroatoms nitrogen, oxygen, and sulfur, and E and G are independently carbon or nitrogen, provided that the 5 membered heteroaryl ring system does not contain more than 3 heteroatoms or more than 1 oxygen or sulfur atom, or a 6 membered heteroaryl ring system, in which x is 1, A, B, E, and G are independently chosen from carbon and nitrogen, provided that the 6 membered heteroaryl ring system does not contain more than 3 nitrogen atoms. The remaining variables, Ar1, Ar2, R, R1, R2, R3, R4, R5, R6, y and z are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of the invention act bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders.

  该发明提供了式（I）中的芳基取代咪唑、吡唑、吡啶和相关化合物，其中由式（A）表示的环系统是一个5成员杂芳基环系统，在该环系统中x为0，A从碳和杂原子氮、氧和硫中选择，E和G分别为碳或氮，前提是5成员杂芳基环系统不含超过3个杂原子或超过1个氧或硫原子，或者是一个6成员杂芳基环系统，在该环系统中x为1，A、B、E和G分别从碳和氮中选择，前提是6成员杂芳基环系统不含超过3个氮原子。其余变量Ar1、Ar2、R、R1、R2、R3、R4、R5、R6、y和z在此处定义。这些化合物是C5a受体的配体。该发明的优选化合物具有高亲和力结合到C5a受体，并且在C5a受体上表现为中性拮抗剂或逆激动剂活性。该发明还涉及包含这些化合物的药物组合物。它进一步涉及使用这些化合物治疗各种炎症和免疫系统疾病。
• [EN] THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSES DE THIAZOLYL UREE POUR LE TRAITEMENT DU CANCER
  申请人：AMGEN INC

  公开号：WO2003070727A1

  公开（公告）日：2003-08-28

  Selected thiazolyl urea compounds of formula (VI) are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stoke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  公式（VI）的选定噻唑基脲类化合物对预防和治疗细胞增殖或凋亡介导的疾病有效。本发明涵盖新的化合物、类似物、前药和其药学上可接受的盐、药物组合物和预防和治疗中风、癌症等疾病及其他疾病或情况的方法。本发明还涉及制备这种化合物的过程以及在这种过程中有用的中间体。
• Aryl imidazoles and related compounds as C5a receptor modulators
  申请人：Neurogen Corporation

  公开号：US20040116424A1

  公开（公告）日：2004-06-17

  The invention provides Aryl substituted imidazoles, pyrazoles, pyridizines and related compounds of the Formula 1 where the ring system represented by 2 is a 5 membered heteroaryl ring system, in which x is 0, A is chosen from carbon and heteroatoms nitrogen, oxygen, and sulfur, and E and G are independently carbon or nitrogen, provided that the 5 membered heteroaryl ring system does not contain more than 3 heteroatoms or more than 1 oxygen or sulfur atom, or a 6 membered heteroaryl ring system, in which x is 1, A, B, E, and G are independently chosen from carbon and nitrogen, provided that the 6 membered heteroaryl ring system does not contain more than 3 nitrogen atoms. The remaining variables, Ar 1 , Ar 2 , R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , y and z are defined herein Such compounds are ligands of C5a receptors. Preferred compounds of the invention act bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptos. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders.

  本发明提供了Formula1的芳基取代咪唑，吡唑，吡啶并咪唑和相关化合物，其中由2表示的环系统是一个五元杂环芳基环系统，在其中x为0，A选择自碳和杂原子氮，氧和硫，并且E和G独立地为碳或氮，前提是五元杂环芳基环系统不含有超过3个杂原子或超过1个氧或硫原子，或者是一个六元杂环芳基环系统，在其中x为1，A，B，E和G独立地选择自碳和氮，前提是六元杂环芳基环系统不含有超过3个氮原子。其余变量，Ar1，Ar2，R，R1，R2，R3，R4，R5，R6，y和z在此定义。这些化合物是C5a受体的配体。本发明的优选化合物具有高亲和力结合C5a受体，并在C5a受体上表现出中和拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的制药组合物。它还涉及使用这些化合物治疗各种炎症和免疫系统紊乱。
• New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators
  申请人：Luke P. George

  公开号：US20070208048A1

  公开（公告）日：2007-09-06

  The invention provides Aryl substituted imidazoles, pyrazoles, pyridizines and related compounds of the Formula where the ring system represented by is a 5 membered heteroaryl ring system, in which x is 0, A is chosen from carbon and heteroatoms nitrogen, oxygen, and sulfur, and E and G are independently carbon or nitrogen provided that the 5 membered heteroaryl ring system does not contain more than 3 heteroatoms or more than 1 oxygen or sulfur atom, or a 6 membered heteroaryl ring system, in which x is 1, A, B, E, and G are independently chosen from carbon and nitrogen, provided that the 6 membered heteroaryl ring system does not contain more than 3 nitrogen atoms. The remaining variables, Ar 1 , Ar 2 , R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , y and z are defined herein Such compounds are ligands of C5a receptors. Preferred compounds of the invention act bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders.

  本发明提供了Aryl取代的咪唑、吡唑、吡啶并相关化合物的公式，其中由环系表示的是一个5元杂环芳基环系，其中x为0，A选择自碳和杂原子氮、氧和硫，而E和G独立地为碳或氮，但5元杂环芳基环系不含有超过3个杂原子或超过1个氧或硫原子，或者是一个6元杂环芳基环系，其中x为1，A、B、E和G独立地选择自碳和氮，但6元杂环芳基环系不含有超过3个氮原子。其余变量Ar1、Ar2、R、R1、R2、R3、R4、R5、R6、y和z在此定义。这些化合物是C5a受体的配体。本发明的优选化合物具有高亲和力结合到C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这种化合物的制药组合物。它还涉及使用这些化合物治疗各种炎症和免疫系统疾病。